EIGR - Eiger BioPharmaceuticals GAAP EPS of -$0.47 misses by $0.08 revenue of $4.64M beats by $0.07M
2023-08-14 17:20:38 ET
- Eiger BioPharmaceuticals press release ( NASDAQ: EIGR ): Q2 GAAP EPS of -$0.47 misses by $0.08 .
- Revenue of $4.64M (+13.4% Y/Y) beats by $0.07M .
- Cash, cash equivalents, and short-term debt securities as of June 30, 2023 totaled $53.6 million, as compared to $98.9 million as of December 31, 2022.
For further details see:
Eiger BioPharmaceuticals GAAP EPS of -$0.47 misses by $0.08, revenue of $4.64M beats by $0.07M